Global Anti-Infectives Market to Reach $103 Billion by 2015: Report

The global market for anti-infective drugs, which mainly includes antibacterials, antivirals, antifungals, and vaccines, is projected to exceed $103 billion by the year 2015, according to a new report from Global Industry Analysts Inc., a San Jose, Calif.-based market research and publishing firm.

The report, titled "Anti-Infectives: A Global Strategic Business Report," says factors driving sales include the introduction of novel therapeutics for drug-resistant bacteria, increasing incidence of severe fungal infections, the potential launch of new antiviral agents, and the introduction of new drugs in the HIV market. Anti-infectives are indicated for the treatment of infections caused by bacteria, fungi, protozoa, prions, and parasites. Other causative agents responsible for developing infectious disorders include chlamydiae, mycoplasmas, worms, rickettsiae, helminths, and yeast.

Antibacterials represent the largest segment of the anti-infectives market globally, and in the antibacterials class, sales are led by cephalosporins, followed by macrolides, fluoroquinolones, and penicillins, the report notes.

Antivirals represent another major anti-infective drug class. Some of the major growth drivers for anti-virals include increased awareness of the disease and its progression, development of novel drug classes, limited generic competition, increased R&D investments fuelled by the growth of drug resistance among patients, and reduction of R&D costs through genomics. According to the report, antiviral drugs are expected to register the fastest growth rate, compared to the other drug classes, including antibacterials, antifungals, and others such as vaccines.

The report provides a comprehensive review of the anti-infectives market by therapeutic class, growth drivers, growth inhibitors, research and development, product introductions, product approvals, and recent industry activity. Key players profiled in the study include Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc, Bayer HealthCare AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline Plc, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi-Aventis SA, Schering-Plough Corp., and Wyeth Pharmaceuticals Inc., among others.

The study provides sales for regions including the United States, Japan, Europe, and the rest of the world collectively. The report also analyzes the market by therapeutic classes, including antibacterials, antivirals, antifungals, and others. Antibacterials are further broken down by drug classes such as Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others. For more details, visit

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Schedule and Record Observations

    IndustrySafe's Observations module allows managers, supervisors, and employees to conduct observations on employees involved in safety critical behavior. IndustrySafe’s pre-built BBS checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Get the Ultimate Guide to Safety Training

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common FAQs.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2019

    June 2019


      New Orleans Networking
      Heed These Summer Safety Tips
      Education, Skill Development, and Behavior Change
      What Good Looks Like
    View This Issue

Bulwark Quiz